Tiziana Life Sciences Secures DoD Grant for Spinal Cord Injury Therapy
Ticker: TLSA · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1723069
Sentiment: bullish
Topics: grant, research, spinal-cord-injury, biotech
TL;DR
Tiziana Life Sciences gets DoD grant for SCI research, potentially boosting their anti-CD3 therapy.
AI Summary
On September 15, 2025, Tiziana Life Sciences Ltd announced it received a research grant from the U.S. Department of Defense (DoD) to study intranasal anti-CD3 therapy for traumatic spinal cord injury (SCI). This funding supports Tiziana's strategic development of its therapeutic approaches.
Why It Matters
This grant from the U.S. Department of Defense validates Tiziana's research into spinal cord injury treatments and could accelerate the development of a novel therapy.
Risk Assessment
Risk Level: medium — While the DoD grant is positive, the success of the research and subsequent commercialization of the therapy carries inherent risks.
Key Players & Entities
- Tiziana Life Sciences Ltd (company) — Company filing the report and recipient of the grant
- U.S. Department of Defense (DoD) (company) — Awarded the research grant
- September 15, 2025 (date) — Date of the announcement
FAQ
What is the specific amount of the research grant awarded by the U.S. Department of Defense?
The filing does not specify the exact dollar amount of the research grant awarded by the U.S. Department of Defense.
What is the primary focus of the research funded by the DoD grant?
The research funded by the DoD grant will focus on studying the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI).
When was this announcement made by Tiziana Life Sciences Ltd?
The announcement was made on September 15, 2025.
What is Tiziana Life Sciences Ltd's strategy that this funding supports?
This funding builds on Tiziana's strategy to develop its therapeutic approaches.
Does Tiziana Life Sciences Ltd file annual reports under Form 20-F or Form 40-F?
Tiziana Life Sciences Ltd indicates it files annual reports under Form 20-F.
Filing Stats: 338 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-09-15 08:00:58
Filing Documents
- ea0257353-6k_tiziana.htm (6-K) — 14KB
- ea025735301ex99-1_tiziana.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-087418.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: September 15, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Press Release, dated September 15, 2025 3